Dr Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Chief Medical Officer of the International Myeloma Foundation (IMF) and serves as a Councillor on the ASH Executive Committee. Dr Mikhael specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis, and Waldenstrom macroglobulinemia. He is the PI of many clinical trials, primarily in relapsed multiple myeloma, and his other clinical research interests include pharmaco-economics, communication skills, and media relations. Dr Mikhael has published over 150 peer-reviewed articles in these fields and lectures internationally on a regular basis. Dr Mikhael recently led the first ever ASCO Guidelines in multiple myeloma and serves on the editorial board of JCO. He serves as a councilor on the executive of the American Society of Hematology (ASH). He is deeply involved in training future researchers and mentors junior faculty worldwide. He now spends nearly 20% of his time in the third world developing collaborations in myeloma and finding ways to enhance access to novel agents.
Dr Mikhael's attendance is kindly supported by Bristol Myers Squibb's sponsorship to the Blood 2021 Meeting.